References
- Capizzi R L. Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Seminars in Oncology 1996; 23(suppl 8): 2–17
- Alberts D. S., Speicher L. A., Krutzch M., Wymer J., Capizzi R. L., Conlon Barrett J., Aickin M. WR-1065, the active metabolite of Amifostine (ethyol) does not inhibit the cytotoxic effect of a broad range of standard anticancer drugs against human ovarian and breast cancer cells. European Journal of cancer 1996; 32A(suppl 4): 17–20
- Douay L., Hu C., Giarratana M. C., Bouchet S., Conlon S., Capizzi R. L., Gorin N K. Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging. Blood 1995; 86: 2849–2855
- Taylor C. W., Wang L. M., List A. F., Fernandez P., Painz-Murrieta G. D., Johnson C. S., Capizzi R L. Amifostine protects normal tissue from paclitaxel toxicity while cytotoxicity against tumour cells in maintained. European Journal of Cancer 1997; 33: 1693–1698
- Valeriote F., Tolen S. Protection and potentiation of nitrogen mustard cytotoxicity by WR 2721. Cancer Research 1982; 42: 4330–4331
- Budd G. T., Ganapathi R., Adelstein D J. Randomized trial of carboplatin alone in patients with advanced solid tumors. Cancer 1997; 80: 1134–1140
- Yuen A. R., Rosenberg S. A., Hoppe R. T., Halpem J. D., Horning S. J. Comparison between conventional salvage therapy and high dose therapy with autolgrafting for recurrent or refractory Hodgkin's disease. Blood 1997; 89: 814–822
- Sweetenham J. W., Pearce R., Taghipour G., Blaise D., Gisselbracht C., Goldstone A H. Adult Burkitt's and Burkitt-like Non Hodgkin's lymphoma-outcome for patients treated with high dose therapy and autologous stemcell transplantation in first remission or at relapse: results from the European group for blood and marrow transplantation. Journal of Clinical Oncology, 14: 2464–2472
- Philip T., Guglielmi C., Hagenbeek A., Somers P., Van der Lelie H., Bron D., Sonnereld P., Gisselbrecht C., Cahu J. Y., Harousseal J L. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non Hodgkin's lymphoma. New England Journal of medicine 1995; 333: 1540–1545
- Hoekman K., Vermorken J B. Incidence and prevention of nonhaematological toxicity of high-dose chemotherapy. Annals of Medicine 1996; 28: 175–182
- Maraninchi D. The clinical consequenses of haematological and nonhaematological toxicity following bone marrow transplantation and the possible impact of haematopoietic growth factors. Bone Marrow Transplantation 1993; 11(suppl2)12–22
- El-Ghissassi F., Verhaeg G., Hainaut P. Modulation of wild-type p 53 protein activity by the aminothiol amifostine. Congress abstact, ASCO. 1997
- Hoper J., Hanjalic A., Sauer R., Plasswilm L. Effect of amifostine (Ethyol) on the development of extraembryonic blood vessels in chick embryos. Strahlentherapie und onkologie 1999; 175(1)28–31
- Murley J. S., Constantinou A., Kamath N. S., Grdina D J. WR-1065, an active metabolite of the cytoprotector amifostine, affects phosphorylation of topoisomerase II alpha leading to changes in enzyme activity and cell cycle progression in CHO AA8cells. Cell Proliferation 1997; 6–7; 283–94
- Liu S. C., Murley J. S, Woloschak G., Grdina D J. Repression of c-myc gene expression by thiol and disulfide forms of the cytoprotector amifostine. Carcinogenesis 1997; 12: 2457–2459